Citation: Madison L. Wallace, Ken S. Rosenthal. Vaccine protection of the mother, the fetus, neonates and infants[J]. AIMS Allergy and Immunology, 2024, 8(2): 124-145. doi: 10.3934/Allergy.2024007
[1] |
Chan MY, Smith MA (2018) Infections in pregnancy. Comprehensive Toxicology. Amsterdam: Elsevier Science 232-249. https://doi.org/10.1016/B978-0-12-801238-3.64293-9 ![]() |
[2] |
Khan AM, Morris SK, Bhutta ZA (2017) Neonatal and perinatal infections. Ped Clin North America 64: 785-798. https://doi.org/10.1016/j.pcl.2017.03.008 ![]() |
[3] |
Etti M, Calvert A, Galiza E, et al. (2022) Maternal vaccination: a review of current evidence and recommendations. Am J Obstet Gynecol 226: 459-474. https://doi.org/10.1016/j.ajog.2021.10.041 ![]() |
[4] |
Kurasawa K (2023) Maternal vaccination-current status, challenges, and opportunities. J Obstet Gynaecol Res 49: 493-509. https://doi.org/10.1111/jog.15503 ![]() |
[5] |
Engmann C, Fleming JA, Khan S, et al. (2020) Closer and closer? Maternal immunization: current promise, future horizons. J Perinatol 40: 844-857. https://doi.org/10.1038/s41372-020-0668-3 ![]() |
[6] |
Mackin DW, Walker SP (2021) The historical aspects of vaccination in pregnancy. Best Practice Res Clin Obstetrics Gyn 76: 13-22. https://doi.org/10.1016/j.bpobgyn.2020.09.005 ![]() |
[7] |
Psarris A, Sindos M, Daskalakis G, et al. (2019) Immunizations during pregnancy: How, when and why. Eur J Obstetrics Gyn Reprod Biol 240: 29-35. https://doi.org/10.1016/j.ejogrb.2019.06.019 ![]() |
[8] |
Giles ML, Way SS, Marchant A, et al. (2023) Maternal vaccination to prevent adverse pregnancy outcomes: An underutilized molecular immunological intervention?. J Mol Biol 435: 168097. https://doi.org/10.1016/j.jmb.2023.168097 ![]() |
[9] | Centers for Disease Control, U.S.A. Immunization Schedules. Available from: https://www.cdc.gov/vaccines/schedules/index.html |
[10] | Centers for Disease Control, U.S.A. Pregnancy and Vaccination. Available from: https://www.cdc.gov/vaccines/pregnancy/index.html |
[11] | (2021) Centers for disease control and preventionEpidemiology and Prevention of Vaccine-Preventable Diseases. “The Pink Book”. Washington: D.C. Public Health Foundation. |
[12] | FDAVaccines Licensed for Use in the United States. Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states |
[13] | Strikas RA (2015) Advisory committee on immunization practices recommended immunization schedules for persons aged 0 through 18 years--United States, 2015. MMWR Morb Mortal Wkly Rep 64: 93-94. https://doi.org/10.1111/ajt.13293 |
[14] | Centers for Disease ControlGuidelines for vaccinating pregnant women. Available from: https://www.cdc.gov/vaccines/pregnancy/hcp-toolkit/guidelines.html#Passive%20Immunization%20During%20Pregnancy |
[15] |
Zhang HQ, Zhang QY, Yuan ZM, et al. (2023) The potential epidemic threat of Ebola virus and the development of a preventive vaccine. J Biosaf Biosecur 5: 67-78. https://doi.org/10.1016/j.jobb.2023.05.001 ![]() |
[16] |
Malik S, Kishore S, Nag S, et al. (2023) Ebola virus disease vaccines: development, current perspectives and challenges. Vaccines 11: 268. https://doi.org/10.3390/vaccines11020268 ![]() |
[17] |
Woolsey C, Geisbert TW (2021) Current state of Ebola virus vaccines: A snapshot. PLoS Pathog 17: e1010078. https://doi.org/10.1371/journal.ppat.1010078 ![]() |
[18] |
Zhang J, Zhang XF, Huang SJ, et al. (2015) Long-term efficacy of a hepatitis E vaccine. N Engl J Med 372: 914-922. https://doi.org/10.1056/NEJMoa1406011 ![]() |
[19] | WHOHepatitis E (2023). Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-e |
[20] |
Ciglenecki I, Rumunu J, Wamala JF, et al. (2022) The first reactive vaccination campaign against hepatitis E. Lancet Inf Dis 22: 1110-1111. https://doi.org/10.1016/S1473-3099(22)00421-2 ![]() |
[21] | Centers for Disease ControlMalaria vaccines. Available from: https://www.cdc.gov/malaria/php/public-health-strategy/malaria-vaccines.html |
[22] |
Björkman A, Benn CS, Aaby P, et al. (2023) RTS, S/AS01 malaria vaccine—proven safe and effective?. Lancet Infect Dis 23: e318-e322. https://doi.org/10.1016/S1473-3099(23)00126-3 ![]() |
[23] |
Verma A, Anand A, Patel VA, et al. (2024) Breaking the malaria barrier: The WHO-approved R21/Matrix-M vaccine and its global impact-an editorial. Ann Med Surg (Lond) 86: 1824-1827. https://doi.org/10.1097/MS9.0000000000001648 ![]() |
[24] | McIntosh EDG (2020) Development of vaccines against the sexually transmitted infections gonorrhoea, syphilis, Chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus. Ther Adv Vaccines Immunother 8. https://doi.org/10.1177/2515135520923887 |
[25] |
De la Maza LM, Darville TL, Pal S (2021) Chlamydia trachomatis vaccines for genital infections: where are we and how far is there to go?. Expert Rev Vaccines 20: 421-435. https://doi.org/10.1080/14760584.2021.1899817 ![]() |
[26] |
Murray SM, McKay PF (2021) Chlamydia trachomatis: Cell biology, immunology and vaccination. Vaccine 39: 2965-2975. https://doi.org/10.1016/j.vaccine.2021.03.043 ![]() |
[27] |
Wagenlehner FME, Naber KG (2019) A step further in a vaccine for Escherichia coli. Lancet Infect Dis 19: 565-567. https://doi.org/10.1016/S1473-3099(19)30069-6 ![]() |
[28] |
Kowarik M, Wetter M, Haeuptle MA, et al. (2021) The development and characterization of an E. coli O25B bioconjugate vaccine. Glycoconj J 38: 421-435. https://doi.org/10.1007/s10719-021-09985-9 ![]() |
[29] |
Mayer RL, Verbeke R, Asselman C, et al. (2022) Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes. Nat Commun 13: 6075. https://doi.org/10.1038/s41467-022-33721-y ![]() |
[30] |
Haese EC, Thai VC, Kahler CM (2021) Vaccine candidates for the control and prevention of the sexually transmitted disease gonorrhea. Vaccines 9: 804. https://doi.org/10.3390/vaccines9070804 ![]() |
[31] |
Jefferson A, Smith A, Fasinu PS, et al. (2021) Sexually transmitted Neisseria gonorrhoeae infections-update on drug treatment and vaccine development. Medicines (Basel) 8: 11. https://doi.org/10.3390/medicines8020011 ![]() |
[32] |
Lin EY, Adamson PC, Klausner JD (2021) Epidemiology, Treatments, and vaccine development for antimicrobial-resistant Neisseria gonorrhoeae: Current strategies and future directions. Drugs 81: 1153-1169. https://doi.org/10.1007/s40265-021-01530-0 ![]() |
[33] |
Johnson B (2023) GSK's gonorrhea vaccine receives fast-track designation to expedite clinical trials. Nature Med 29: 2146-2147. https://doi.org/10.1038/d41591-023-00069-9 ![]() |
[34] |
Scully IL, Timofeyeva Y, Illenberger A, et al. (2021) Performance of a four-antigen Staphylococcus aureus vaccine in preclinical models of invasive S. aureus disease. Microorg 15: 177. https://doi.org/10.3390/microorganisms9010177 ![]() |
[35] |
Madhi SA, Anderson AS, Absalon J, et al. (2023) Potential for maternally administered vaccine for infant Group B Streptococcus. N Engl J Med 389: 215-227. https://doi.org/10.1056/NEJMoa2116045 ![]() |
[36] |
Mahmoud A, Toth I, Stephenson R (2022) Developing an effective glycan-based vaccine for Streptococcus pyogenes. Angew Chem Int Ed 61. https://doi.org/10.1002/anie.202115342 ![]() |
[37] |
Smeesters PR, de Crombrugghe G, Tsoi SK, et al. (2024) Global Streptococcus pyogenes strain diversity, disease associations, and implications for vaccine development: A systematic review. Lancet Microbe 5: e181-e193. https://doi.org/10.1016/S2666-5247(23)00318-X ![]() |
[38] |
Walkinshaw DR, Wright MEE, Mullin AE, et al. (2023) The Streptococcus pyogenes vaccine landscape. npj Vaccines 8: 16. https://doi.org/10.1038/s41541-023-00609-x ![]() |
[39] |
Kojima N, Konda KA, Klausner JD (2022) Notes on syphilis vaccine development. Front Immunol 13: 952284. https://doi.org/10.3389/fimmu.2022.952284 ![]() |
[40] |
Noda AA, Méndez M, Rodríguez I, et al. (2022) Genetic recombination in treponema pallidum: implications for diagnosis, epidemiology, and vaccine development. Sex Transm Dis 49: e7-e10. https://doi.org/10.1097/OLQ.0000000000001497 ![]() |
[41] |
Scarpini S, Morigi F, Betti L, et al. (2021) Development of a vaccine against human cytomegalovirus: advances, barriers, and implications for the clinical practice. Vaccines 9: 551. https://doi.org/10.3390/vaccines9060551 ![]() |
[42] |
Schleiss MR, Diamond DJ (2020) Exciting times for cytomegalovirus (CMV) vaccine development: Navigating the pathways toward the goal of protecting infants against congenital CMV infection. Vaccines 8: 526. https://doi.org/10.3390/vaccines8030526 ![]() |
[43] |
Hu X, Wang HY, Otero CE, et al. (2022) Lessons from acquired natural immunity and clinical trials to inform next-generation human cytomegalovirus vaccine development. Ann Rev Vir 9: 491-520. https://doi.org/10.1146/annurev-virology-100220-010653 ![]() |
[44] |
Yechezkel I, Law M, Tzarum N (2021) From structural studies to HCV vaccine design. Viruses 13: 833. https://doi.org/10.3390/v13050833 ![]() |
[45] |
Malik S, Sah R, Ahsan O, et al. (2023) Insights into the novel therapeutics and vaccines against herpes simplex virus. Vaccines 11: 325. https://doi.org/10.3390/vaccines11020325 ![]() |
[46] |
Chentoufi A, Dhanushkodi NR, Srivastava R, et al. (2022) Combinatorial herpes simplex vaccine strategies: From bedside to bench and back. Front Immunol 13. https://doi.org/10.3389/fimmu.2022.849515 ![]() |
[47] |
Awasthi S, Friedman HM (2021) An mRNA vaccine to prevent genital herpes. Trans Res 242: 56-65. https://doi.org/10.1016/j.trsl.2021.12.006 ![]() |
[48] |
Stanfield BA, Kousoulas KG, Fernandez A, et al. (2021) Rational design of live-attenuated vaccines against herpes simplex viruses. Viruses 13: 1637. https://doi.org/10.3390/v13081637 ![]() |
[49] |
Ng'uni T, Chasara C, Ndhlovu ZM (2020) Major scientific hurdles in HIV vaccine development: historical perspective and future directions. Front Immunol 11: 590780. https://doi.org/10.3389/fimmu.2020.590780 ![]() |
[50] |
Nkolola JP, Barouch DH (2023) Prophylactic HIV-1 vaccine trials: past, present, and future. Lancet 11: E117-E124. https://doi.org/10.1016/S2352-3018(23)00264-3 ![]() |
[51] |
Schiffner T, Phung I, Ray R, et al. (2024) Vaccination induces broadly neutralizing antibody precursors to HIV gp41. Nat Immunol 25: 1073-1082. https://doi.org/10.1038/s41590-024-01833-w ![]() |
[52] |
Leggat DJ, Cohen KW, Willis JR, et al. (2022) Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science 378: eadd6502. https://doi.org/10.1126/science.add6502 ![]() |
[53] |
Haynes BF, Wiehe K, Borrow P, et al. (2023) Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat Rev Immunol 23: 142-158. https://doi.org/10.1038/s41577-022-00753-w ![]() |
[54] |
Matarazzo L, Bettencourt PJG (2023) mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV. Front Immunol 14. https://doi.org/10.3389/fimmu.2023.1172691 ![]() |
[55] |
Suzuki H, Noguchi T, Matsugu N, et al. (2022) Safety and immunogenicity of parvovirus B19 virus-like particle vaccine lacking phospholipase A2 activity. Vaccine 40: 6100-6106. https://doi.org/10.1016/j.vaccine.2022.09.009 ![]() |
[56] |
Zhang Y, Li D, Lu S, et al. (2022) Toxoplasmosis vaccines: what we have and where to go?. Npj Vaccines 7: 131. https://doi.org/10.1038/s41541-022-00563-0 ![]() |
[57] |
Wang Y, Ling L, Zhang Z, et al. (2022) Current advances in Zika vaccine development. Vaccines (Basel) 10: 1816. https://doi.org/10.3390/vaccines10111816 ![]() |
[58] |
Pielnaa P, Al-Saadawe M, Saro A, et al. (2020) Zika virus-spread, epidemiology, genome, transmission cycle, clinical manifestation, associated challenges, vaccine and antiviral drug development. Virology 543: 34-42. https://doi.org/10.1016/j.virol.2020.01.015 ![]() |
[59] |
Mordmüller B, Sulyok M, Egger-Adam D, et al. (2019) First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, a vaccine candidate to prevent pregnancy-associated malaria. Clin Infect Dis 69: 1509-1516. https://doi.org/10.1093/cid/ciy1140 ![]() |
[60] |
Sirima SB, Richert L, Chêne A, et al. (2020) PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study. Lancet Infect Dis 20: 585-597. https://doi.org/10.1016/S1473-3099(19)30739-X ![]() |
[61] |
Kochhar S, Bonhoeffer J, Jones CE, et al. (2017) Immunization in pregnancy clinical research in low and middle income countries: study design, regulatory and safety considerations. Vaccine 35: 6575-6581. https://doi.org/10.1016/j.vaccine.2017.03.103 ![]() |
[62] | Centers for Disease Control and PreventionVaccine Adverse Event Reporting System (VAERS) (2021). Available from: https://vaers.hhs.gov/ |
[63] |
Healy SA, Fried M, Richie T, et al. (2019) Malaria vaccine trials in pregnant women: An imperative without precedent. Vaccine 37: 763-770. https://doi.org/10.1016/j.vaccine.2018.12.025 ![]() |
[64] | U.S. Food and Drug AdministrationFDA approves first vaccine for pregnant individuals to prevent rsv in infants (2023). Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants |
[65] | Centers for Disease Control and PreventionCOVID-19 vaccines while pregnant or breastfeeding (2019). Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html |
[66] |
Badell ML, Dude CM, Rasmussen SA, et al. (2022) COVID-19 vaccination in pregnancy. BMJ 378: e069741. https://doi.org/10.1136/bmj-2021-069741 ![]() |
[67] |
Mitchell SL, Schulkin J, Power ML (2023) Vaccine hesitancy in pregnant women: A narrative review. Vaccine 41: 4220-4227. https://doi.org/10.1016/j.vaccine.2023.05.047 ![]() |
[68] |
Tuckerman J, Kaufman J, Danchin M (2022) Effective approaches to combat vaccine hesitancy. Pediatr Infect Dis J 41: e243-e245. https://doi.org/10.1097/INF.0000000000003499 ![]() |
[69] |
Kuehn M, LaMori J, DeMartino JK, et al. (2022) Assessing barriers to access and equity for COVID-19 vaccination in the US. BMC Public Health 22: 2263. https://doi.org/10.1186/s12889-022-14636-1 ![]() |
[70] |
Howard FHN, Kwan A, Winder N, et al. (2022) Understanding immune responses to viruses-do underlying Th1/Th2 cell biases predict outcome?. Viruses 14: 1493. https://doi.org/10.3390/v14071493 ![]() |
[71] |
Kim YH, Hong KJ, Kim H, et al. (2022) Influenza vaccines: past, present, and future. Rev Med Virol 32: e2243. https://doi.org/10.1002/rmv.2243 ![]() |
[72] |
Aleebrahim-Dehkordi E, Molavi B, Mokhtari M, et al. (2022) T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses. Transpl Immunol 70: 101495. https://doi.org/10.1016/j.trim.2021.101495 ![]() |
[73] |
Rappuoli R, De Gregorio E, Costantino P (2018) On the mechanisms of conjugate vaccines. Proc Natl Acad Sci USA 116: 14-16. https://doi.org/10.1073/pnas.1819612116 ![]() |
[74] |
Sallusto F, Lanzavecchia A, Araki K, et al. (2010) From vaccines to memory and back. Immunity 33: 451-463. https://doi.org/10.1016/j.immuni.2010.10.008 ![]() |
[75] |
Siegrist CA (2008) Vaccine immunology. Vaccines 5: 17-36. https://doi.org/10.1016/B978-1-4160-3611-1.50006-4 ![]() |
[76] |
Wang Q, Tan MT, Keegan BP, et al. (2014) Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation. Biomaterials 35: 8385-8393. https://doi.org/10.1016/j.biomaterials.2014.05.067 ![]() |
[77] |
Pyzik M, Kozicky LK, Gandhi AK, et al. (2023) The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol 23: 415-432. https://doi.org/10.1038/s41577-022-00821-1 ![]() |
[78] |
Li Z, Palaniyandi S, Zeng R, et al. (2011) Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci USA 108: 4388-4393. https://doi.org/10.1073/pnas.1012861108 ![]() |
[79] |
Palmeira P, Quinello C, Silveira-Lessa AL, et al. (2012) IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012: 985646. https://doi.org/10.1155/2012/985646 ![]() |
[80] | Li Y, Jin L, Chen T (2020) The effects of secretory IgA in the mucosal immune system. Biomed Res Int 2020: 2032057. https://doi.org/10.1155/2020/2032057 |
[81] |
Correa VA, Portilho AI, De Gaspari E (2022) Vaccines, adjuvants and key factors for mucosal immune response. Immunology 167: 124-138. https://doi.org/10.1111/imm.13526 ![]() |
[82] |
Mor G, Aldo P, Alvero A (2017) The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol 17: 469-482. https://doi.org/10.1038/nri.2017.64 ![]() |
[83] |
Philbin VJ, Levy O (2009) Developmental biology of the innate immune response: implications for neonatal and infant vaccine development. Pediatr Res 65: 98R-105R. https://doi.org/10.1203/PDR.0b013e31819f195d ![]() |
[84] |
Basha S, Surendran N, Pichichero M (2014) Immune responses in neonates. Expert Rev Clin Immunol 10: 1171-1184. https://doi.org/10.1586/1744666X.2014.942288 ![]() |
[85] |
Whittaker E, Goldblatt D, McIntyre P, et al. (2018) Neonatal immunization: Rationale, current state, and future prospects. Front Immunol 9: 532. https://doi.org/10.3389/fimmu.2018.00532 ![]() |
[86] |
Semmes EC, Chen JL, Goswami R, et al. (2021) Understanding early-life adaptive immunity to guide interventions for pediatric health. Front Immunol 11. https://doi.org/10.3389/fimmu.2020.595297 ![]() |
[87] |
Apostol AC, Jensen KDC, Beaudin AE (2020) training the fetal immune system through maternal inflammation—A layered hygiene hypothesis. Front Immunol 11. https://doi.org/10.3389/fimmu.2020.00123 ![]() |
[88] |
Yu JC, Khodadadi H, Malik A, et al. (2018) Innate immunity of neonates and infants. Front Immunol 9: 1759. https://doi.org/10.3389/fimmu.2018.01759 ![]() |
[89] |
Megli CJ, Coyne CB (2022) Infections at the maternal–fetal interface: an overview of pathogenesis and defence. Nat Rev Microbiol 20: 67-82. https://doi.org/10.1038/s41579-021-00610-y ![]() |
[90] |
Camacho-Gonzalez A, Spearman PW, Stoll BJ (2013) Neonatal infectious diseases: evaluation of neonatal 9. Pediatr Clin North Am 60: 367-389. https://doi.org/10.1016/j.pcl.2012.12.003 ![]() |
[91] |
Atyeo C, Alter G (2021) The multifaceted roles of breast milk antibodies. Cell 184: 1486-1499. https://doi.org/10.1016/j.cell.2021.02.031 ![]() |
[92] |
Kumar M, Saadaoui M, Al Khodor S (2022) Infections and pregnancy: Effects on maternal and child health. Front Cell Infect Microbiol 12: 873253. https://doi.org/10.3389/fcimb.2022.873253 ![]() |
[93] |
Yockey LJ, Lucas C, Iwasaki A (2020) Contributions of maternal and fetal antiviral immunity in congenital disease. Science 368: 608-612. https://doi.org/10.1126/science.aaz1960 ![]() |
[94] |
Kwon S, Joshi AD, Lo CH, et al. (2021) Association of social distancing and face mask use with risk of COVID-19. Nat Commun 12: 3737. https://doi.org/10.1038/s41467-021-24115-7 ![]() |
[95] |
Mallory ML, Lindesmith LC, Baric RS (2018) Vaccination-induced herd immunity: Successes and challenges. J Allergy Clin Immunol 142: 64-66. https://doi.org/10.1016/j.jaci.2018.05.007 ![]() |
[96] |
Amaral E, Money D, Jamieson D, et al. (2023) Vaccination during pregnancy: A golden opportunity to embrace. Int J Gynecol Obstet 163: 476-483. https://doi.org/10.1002/ijgo.14981 ![]() |
[97] |
Gigi CE, Anumba DOC (2021) Parvovirus B19 infection in pregnancy-A review. Eur J Obstet Gynecol Reprod Biol 264: 358-362. https://doi.org/10.1016/j.ejogrb.2021.07.046 ![]() |
[98] |
Leruez-Ville M, Foulon I, Pass R, et al. (2020) Cytomegalovirus infection during pregnancy: state of the science. Am J Obstetrics Gynecology 223: 330-349. https://doi.org/10.1016/j.ajog.2020.02.018 ![]() |
[99] |
Pesch MH, Schleiss MR (2022) Emerging concepts in congenital cytomegalovirus. Pediatrics 150: e2021055896. https://doi.org/10.1542/peds.2021-055896 ![]() |
[100] |
Gerna G, Fornara C, Furione M, et al. (2021) Congenital human cytomegalovirus infection: A narrative review of maternal immune response and diagnosis in view of the development of a vaccine and prevention of primary and non-primary infections in pregnancy. Microorganisms 9: 1749. https://doi.org/10.3390/microorganisms9081749 ![]() |
[101] |
Marchant A, Sadarangani M, Garand M, et al. (2017) Maternal immunisation: collaborating with mother nature. Lancet Infect Dis 17: e197-e208. https://doi.org/10.1016/S1473-3099(17)30229-3 ![]() |
[102] | Immunization Action CoalitionVaccinations for pregnant women. Available from: https://www.immunize.org/nslt.d/n63/vacs_pregnant_women.pdf |
[103] |
Pollard AJ, Bijker EM (2021) A guide to vaccinology: From basic principles to new developments. Nat Rev Immunol 21: 83-100. https://doi.org/10.1038/s41577-020-00479-7 ![]() |
[104] | World Health OrganizationGuidelines for developing a national immunization strategy. Available from: https://iris.who.int/bitstream/handle/10665/351144/WHO-IVB-2021.05-eng.pdf |
[105] |
Slifka MK, Amanna IJ (2018) Passive immunization. Plotkin's Vaccines. Amsterdam: Elsevier Science 84-95. e10. https://doi.org/10.1016/B978-0-323-35761-6.00008-0 ![]() |
[106] |
Hammitt LL, Dagan R, Yuan Y, et al. (2022) Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med 386: 837-846. https://doi.org/10.1056/NEJMoa2110275 ![]() |
[107] |
Terrault NA, Levy MT, Cheung KW, et al. (2021) Viral hepatitis and pregnancy. Nat Rev Gastroenterol Hepatol 18: 117-130. https://doi.org/10.1038/s41575-020-00361-w ![]() |
[108] | Lange C, Aaby P, Behr MA, et al. (2021) 100 years of Mycobacterium bovis bacille Calmette-Guérin. Lancet Infect Dis . https://doi.org/10.1016/S1473-3099(21)00403-5 |
[109] | WHONew TB Vaccine Research. Available from: https://www.who.int/teams/global-tuberculosis-programme/research-innovation/vaccines |
[110] |
Lai R, Ogunsola AF, Rakib T, et al. (2023) Key advances in vaccine development for tuberculosis—success and challenges. npj Vaccines 8: 158. https://doi.org/10.1038/s41541-023-00750-7 ![]() |
[111] | Hongmin K, Han-Gyu C, Sung Jae S (2023) Bridging the gaps to overcome major hurdles in the development of next-generation tuberculosis vaccines. Front Immunol 14. https://doi.org/10.3389/fimmu.2023.1193058 |
[112] | Concepcion F, Estivariz MD, Link-Gelles R, et al. (2021) Poliomyelitis. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. “The Pink Book”. Washington: D.C. Public Health Foundation. |
[113] |
O'Ryan M (2017) Rotavirus Vaccines: a story of success with challenges ahead. F1000Res 6: 1517. https://doi.org/10.12688/f1000research ![]() |
[114] |
Connolly SA, Jardetzky TS, Longnecker R (2021) The structural basis of herpesvirus entry. Nat Rev Microbiol 19: 110-121. https://doi.org/10.1038/s41579-020-00448-w ![]() |
[115] |
Ruckwardt TJ (2023) The road to approved vaccines for respiratory syncytial virus. npj Vaccines 8: 138. https://doi.org/10.1038/s41541-023-00734-7 ![]() |
[116] |
Barouch D (2022) COVID-19 vaccines—immunity, variants, boosters. N Engl J Med 387: 1011-1020. https://doi.org/10.1056/NEJMra2206573 ![]() |
[117] | Centers for Disease ControlVaccine Effectiveness: How Well Do Flu Vaccines Work?. Available from https://www.cdc.gov/flu/vaccines-work/vaccineeffect.htm |
[118] | Centers for Disease ControlSelecting Viruses for the Seasonal Influenza Vaccine. Available from: https://www.cdc.gov/flu/prevent/vaccine-selection.htm |
[119] | Centers for Disease Control.Use of an additional updated 2023–2024 covid-19 vaccine dose for adults aged ≥ 65 years: Recommendations of the advisory committee on immunization practices—united states, 2024. MMWR (2024) 73: 377-381. https://doi.org/10.15585/mmwr.mm7316a4 |
[120] |
Masomian M, Ahmad Z, Gew LT, et al. (2020) Development of next generation Streptococcus pneumoniae vaccines conferring broad protection. Vaccines 8: 132. https://doi.org/10.3390/vaccines8010132 ![]() |
[121] |
Li S, Liang H, Zhao SH, et al. (2023) Recent progress in pneumococcal protein vaccines. Front Immunol 14: 1278346. https://doi.org/10.3389/fimmu.2023.1278346 ![]() |
[122] |
Dhama K, Dhawan M, Tiwari R, et al. (2022) COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges. Hum Vaccin Immunother 18: 2045853. https://doi.org/10.1080/21645515.2022.2045853 ![]() |
[123] |
Salloum M, Paviotti A, Bastiaens H, et al. (2023) The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023. Vaccine 41: 7076-7083. https://doi.org/10.1016/j.vaccine.2023.10.057 ![]() |
[124] |
Matić Z, Šantak M (2022) Current view on novel vaccine technologies to combat human infectious diseases. Appl Microbiol Biotechnol 106: 25-56. https://doi.org/10.1007/s00253-021-11713-0 ![]() |
[125] |
Zhao T, Cai Y, Jiang Y, et al. (2023) Vaccine adjuvants: mechanisms and platforms. Sig Transduct Target Ther 8: 283. https://doi.org/10.1038/s41392-023-01557-7 ![]() |
[126] |
Rzymski P, Szuster-Ciesielska A, Dzieciątkowski T, et al. (2023) mRNA vaccines: The future of prevention of viral infections?. J Med Virol 95: e28572. https://doi.org/10.1002/jmv.28572 ![]() |
[127] |
Nagashima KA, Mousa JJ (2021) Next-generation influenza HA immunogens and adjuvants in pursuit of a broadly protective vaccine. Viruses 13: 546. https://doi.org/10.3390/v13040546 ![]() |
[128] |
Rappuoli R, Bottomley MJ, D'Oro U, et al. (2016) Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J Exp Med 213: 469-481. https://doi.org/10.1084/jem.20151960 ![]() |
[129] |
Pagliari S, Dema B, Sanchez-Martinez A, et al. (2023) DNA vaccines: history, molecular mechanisms and future perspectives. J Mol Biol 435: 168297. https://doi.org/10.1016/j.jmb.2023.168297 ![]() |
[130] |
Slütter B, Jiskoot W (2016) Sizing the optimal dimensions of a vaccine delivery system: a particulate matter. Expert Opin Drug Deliv 13: 167-170. https://doi.org/10.1517/17425247.2016.1121989 ![]() |
[131] |
Facciolà A, Visalli G, Laganà A, et al. (2022) An overview of vaccine adjuvants: Current evidence and future perspectives. Vaccines 10: 819. https://doi.org/10.3390/vaccines10050819 ![]() |
[132] |
Nesbitt RC, Asilaza VK, Gignoux E, et al. (2024) Vaccination coverage and adverse events following a reactive vaccination campaign against hepatitis E in Bentiu displaced persons camp, South Sudan. PLoS Negl Trop Dis 18: e0011661. https://doi.org/10.1371/journal.pntd.0011661 ![]() |
[133] |
Gigi CE, Anumba DOC (2021) Parvovirus B19 infection in pregnancy-A review. Eur J Obstet Gynecol Reprod Biol 264: 358-362. https://doi.org/10.1016/j.ejogrb.2021.07.046 ![]() |
[134] |
Dittmer FP, Guimarães CM, Peixoto AB, et al. (2024) Parvovirus B19 infection and pregnancy: Review of the current knowledge. J Pers Med 14: 139. https://doi.org/10.3390/jpm14020139 ![]() |
[135] |
Sartori P, Egloff C, Hcini N, et al. (2023) Primary, secondary, and tertiary prevention of congenital cytomegalovirus infection. Viruses 15: 819. https://doi.org/10.3390/v15040819 ![]() |
[136] |
Adugna A (2023) Therapeutic strategies and promising vaccine for hepatitis C virus infection. Immun Inflamm Dis 11: e977. https://doi.org/10.1002/iid3.977 ![]() |
[137] |
Fuerst TR, Pierce BG, Keck ZY, et al. (2018) Designing a B cell-based vaccine against a highly variable hepatitis C virus. Front Microbiol 8. https://doi.org/10.3389/fmicb.2017.02692 ![]() |
[138] |
Zhao Q, He K, Zhang X, et al. (2022) Production and immunogenicity of different prophylactic vaccines for hepatitis C virus (Review). Exp Ther Med 24: 474. https://doi.org/10.3892/etm.2022.11401 ![]() |